Markets
markets

Dick’s Sporting Goods scores Q4 earnings beat, but stock is down for the count after guidance strikes out

Shares of Dick’s Sporting Goods fell about 6% early Tuesday afternoon, on pace for their worst day since last July, even after the sports retailer scored a Q4 earnings beat. Revenue for the quarter came in at $3.89 billion, versus FactSet analysts’ estimates of $3.77 billion. Earnings per share also topped expectations, reaching $3.62.

But the outlook was more rocky: Dick’s is expecting full-year earnings per share to be between $13.80 and $14.40, short of Wall Street estimates of $14.82, according to FactSet. Meanwhile, net sales are expected to be between $13.6 billion and $13.9 billion, which is in line with the higher end of estimates of $13.88 billion. Shares of Dick’s Sporting Goods are still nearly 10% higher over the past year.

In the upcoming year, Dick’s plans to spend $1 billion on a net basis to build 16 of its 100,000-square-foot House of Sport locations. Dick’s also plans to capitalize on the rising popularity of women’s sports and the World Cup soccer matches in the US next year.

But the outlook was more rocky: Dick’s is expecting full-year earnings per share to be between $13.80 and $14.40, short of Wall Street estimates of $14.82, according to FactSet. Meanwhile, net sales are expected to be between $13.6 billion and $13.9 billion, which is in line with the higher end of estimates of $13.88 billion. Shares of Dick’s Sporting Goods are still nearly 10% higher over the past year.

In the upcoming year, Dick’s plans to spend $1 billion on a net basis to build 16 of its 100,000-square-foot House of Sport locations. Dick’s also plans to capitalize on the rising popularity of women’s sports and the World Cup soccer matches in the US next year.

More Markets

See all Markets
markets

Canopy rallies after CEO stock purchase

Canopy Growth rallied on Wednesday after its CEO, Luc Mongeau, disclosed an unplanned stock purchase on Tuesday.

Mongeau, who joined Canopy from Mars in January, bought 27,469 shares at CA$1.84. The buy is worth about US$36,259.

It has been a tumultuous time for cannabis stocks, as the market in Canada (where Canopy is located) stagnates and cannabis reform in the US has yet to move forward.

markets

Robinhood, new S&P 500 leader, the subject of favorable analyst chatter

Robinhood Markets briefly touched a new all-time intraday high in early trading after the newly minted — and now top-performing — member of the the S&P 500 received some favorable write-ups from Wall Street analysts.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. I own stock as part of my compensation.)

Piper Sandler analysts highlighted momentum in the company’s prediction markets business thanks to the rollout of contracts on college and profession football, noting that the event contracts business was running at a $200 million annualized rate so far in September. They raised their price target on the shares to $140 from $120.

“Prediction Markets (aka event contracts) present significant upside opportunity for Robinhood,” Piper Sandler’s Patrick Moley wrote.

Elsewhere, Citi analysts raised their Q3 and full-year 2025 estimates and upped their price target on the shares to $135, but kept a “neutral” rating on the stock.

“While HOOD continues to see solid momentum across the platform, we believe the stock is pricing in much of the growth potential in our view. Given current valuations and where we are in the retail cycle (closer to the highs than the lows from an activity perspective from our viewpoint), we prefer to wait for a more reasonable entry point at present.”

The stock has clearly had a heck of a run.

Through yesterday’s close, Robinhood was up nearly 240% in 2025. Since it was added to the S&P 500 on Monday, it’s now the top performer among the blue chips, trouncing previous leaders Seagate Technology Holdings and Palantir.

markets

UniQure surges after encouraging trial results for Huntington’s treatment

UniQure rose more than 150% in early trading Wednesday after it released trial results that showed its experimental gene therapy for Huntington’s disease slowed its progression by 75% after three years.

The treatment, AMT-130, is a one-time treatment for Huntington’s, a genetic brain disease that degrades cognitive function and muscle control. There is currently no cure for the disease.

UniQure said it plans to submit the treatment for approval to the Food and Drug Administration in the first quarter of 2026, meaning it could become available to patients later that year. The company currently makes nearly all of its revenue from gene therapies that treat hemophilia.

Halo of the sun

A tiny UK company is showing how easy it is to get an (undeserved?) Nvidia halo effect

Step 1: join a free Nvidia program. Step 2: watch stock go up. Step 3: watch stock go down.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.